Victoria L. Fleming, Jamie Peven, Brian C. Helsel, Lauren T. Ptomey, Julianne Clina, Ashlyn Barry, Beau M. Ances, Benjamin L. Handen, Bradley T. Christian, Charles Laymon, Matthew Zammit, Elizabeth Head, Mark Mapstone, Ozioma Okonkwo, Sigan L. Hartley, for the Alzheimer Biomarkers Consortium – Down Syndrome
{"title":"Physical activity as a resistance or resilience mechanism in Down syndrome Alzheimer's disease","authors":"Victoria L. Fleming, Jamie Peven, Brian C. Helsel, Lauren T. Ptomey, Julianne Clina, Ashlyn Barry, Beau M. Ances, Benjamin L. Handen, Bradley T. Christian, Charles Laymon, Matthew Zammit, Elizabeth Head, Mark Mapstone, Ozioma Okonkwo, Sigan L. Hartley, for the Alzheimer Biomarkers Consortium – Down Syndrome","doi":"10.1002/trc2.70127","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Adults with Down syndrome (DS) are at risk for Alzheimer's disease (AD). Lifestyle factors such as engagement in moderate-to-vigorous physical activity (MVPA) reduce risk or delay the onset of AD. This study aimed to determine whether MVPA confers a <i>resistance</i> (AD pathology) or <i>resilience</i> (cognitive decline) effect on the relationship between AD pathology and cognitive decline in DS.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>Analyses included 69 adults with DS (aged 26–58) who participated in a longitudinal study across 3.29 years. An actigraphy accelerometer assessed MVPA across 7 days. Directly administered and informant-reported measures assessed cognitive functioning, specifically memory and dementia symptoms. Neuroimaging biomarkers quantified amyloid beta (Aβ) burden, as assessed via positron emission tomography imaging.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>In regression models, baseline MVPA was not associated with baseline level or change in global Aβ burden across 32 months. However, baseline MVPA (<i>β</i> = −0.005 to −0.004, <i>p</i> < 0.05) significantly moderated the association between increases in Aβ burden and declines in cognitive functioning. Adults with DS who engaged in greater MVPA experienced less cognitive decline compared to adults with DS who engaged in less MVPA, who had similar Aβ load.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>MVPA may help maintain cognitive functioning early in the progression of AD pathology in adults with DS.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Adults with Down syndrome are genetically at risk for Alzheimer's disease (AD).</li>\n \n <li>Timing of AD clinical onset spans 30+ years.</li>\n \n <li>Physical activity has been linked to less cognitive decline and dementia symptoms.</li>\n \n <li>Physical activity may protect against dementia through resilience mechanisms.</li>\n \n <li>Physical activity could be a low-cost intervention to help prevent cognitive decline.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 3","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70127","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/trc2.70127","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
INTRODUCTION
Adults with Down syndrome (DS) are at risk for Alzheimer's disease (AD). Lifestyle factors such as engagement in moderate-to-vigorous physical activity (MVPA) reduce risk or delay the onset of AD. This study aimed to determine whether MVPA confers a resistance (AD pathology) or resilience (cognitive decline) effect on the relationship between AD pathology and cognitive decline in DS.
METHODS
Analyses included 69 adults with DS (aged 26–58) who participated in a longitudinal study across 3.29 years. An actigraphy accelerometer assessed MVPA across 7 days. Directly administered and informant-reported measures assessed cognitive functioning, specifically memory and dementia symptoms. Neuroimaging biomarkers quantified amyloid beta (Aβ) burden, as assessed via positron emission tomography imaging.
RESULTS
In regression models, baseline MVPA was not associated with baseline level or change in global Aβ burden across 32 months. However, baseline MVPA (β = −0.005 to −0.004, p < 0.05) significantly moderated the association between increases in Aβ burden and declines in cognitive functioning. Adults with DS who engaged in greater MVPA experienced less cognitive decline compared to adults with DS who engaged in less MVPA, who had similar Aβ load.
DISCUSSION
MVPA may help maintain cognitive functioning early in the progression of AD pathology in adults with DS.
Highlights
Adults with Down syndrome are genetically at risk for Alzheimer's disease (AD).
Timing of AD clinical onset spans 30+ years.
Physical activity has been linked to less cognitive decline and dementia symptoms.
Physical activity may protect against dementia through resilience mechanisms.
Physical activity could be a low-cost intervention to help prevent cognitive decline.
期刊介绍：
Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
